Airway hyperresponsiveness to cigarette smoke in ovalbumin-sensitized guinea pigs.
This study was carried out to determine if the bronchoconstrictive effect of cigarette smoke (CS) is enhanced when airway hyperresponsiveness is induced by ovalbumin (Ova) sensitization, and if so, whether an increase in endogenously released tachykinins is involved. The bronchoconstrictive effects of an acute CS inhalation challenge (15 ml; 50% concentration) were compared between guinea pigs sensitized with aerosolized Ova and matching control animals (receiving saline aerosol). In Ova-sensitized animals, there were marked increases in the numbers of eosinophils and neutrophils in the bronchoalveolar lavage fluid (BALF), which was accompanied by an elevated bronchomotor response to acetylcholine (ACh). The baseline lung resistance (RL) and dynamic pulmonary compliance (Cdyn) were not significantly different between the two groups; however, the same CS inhalation challenge evoked a significantly more intense bronchoconstriction in the Ova-sensitized group (control group: DeltaRL = 68 +/- 8%, DeltaCdyn = -26 +/- 6%; Ova group: DeltaRL = 425 +/- 76%; DeltaCdyn = -47 +/- 8%). The levels of substance P-like immunoreactivity (SP-LI) and calcitonin gene-related peptide-like immunoreactivity (CGRP-LI) measured in the bronchoalveolar lavage (BAL) collected after CS inhalation challenge were also significantly greater in Ova-sensitized animals than in control animals. Furthermore, pretreatment with SR-48968, a selective antagonist of neurokinin-2 (NK(2)) receptor, inhibited more than 85% of the enhanced bronchomotor responses to CS challenge, but did not significantly reduce the airway hyperresponsiveness to ACh in Ova-sensitized guinea pigs. These results show that Ova sensitization induces airway hyperresponsiveness to inhaled CS, and that the endogenous tachykinins evoked by CS-induced activation of lung C fibers play a primary role in this augmented response.
Wu
Z X
ZX
Department of Physiology and Division of Allergy and Immunology, University of Kentucky, Lexington, Kentucky 40536-0084, USA.
Zhou
D
D
Chen
G
G
Lee
L Y
LY
D000109:Acetylcholine / Q000494:pharmacology; D000403:Airway Resistance; D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D016535:Bronchial Hyperreactivity / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D016084:Bronchoconstriction / Q000502:physiology*; D015740:Calcitonin Gene-Related Peptide / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D004804:Eosinophils / Q000166:cytology; D006168:Guinea Pigs; D007958:Leukocyte Count; D008168:Lung / Q000187:drug effects / Q000503:physiopathology*; D008170:Lung Compliance; D008297:Male; D009504:Neutrophils / Q000166:cytology; D010047:Ovalbumin / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D010947:Plants, Toxic; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors; D012906:Smoke / Q000009:adverse effects*; D014026:Nicotiana
D001549:Benzamides; D010880:Piperidines; D018041:Receptors, Neurokinin-2; D012906:Smoke; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine; C073839:SR 48968; D010047:Ovalbumin; D015740:Calcitonin Gene-Related Peptide; D000109:Acetylcholine